Jagsonpal Pharmaceuticals trades jubilantly on entering into agreement with Suvinys Developers

Jagsonpal Pharmaceuticals is currently trading at Rs. 194.40, up by 17.05 points or 9.61% from its previous closing of Rs. 177.35 on the BSE.

Jagsonpal Pharmaceuticals
Jagsonpal Pharmaceuticals

The scrip opened at Rs. 177.35 and has touched a high and low of Rs. 194.40 and Rs. 175.20 respectively. So far 19903 shares were traded on the counter.

You Can Also Read This  India Cements reports 94% fall in Q2 net profit

The BSE group ‘B’ stock of face value Rs. 5 has touched a 52 week high of Rs. 203.25 on 03-Aug-2021 and a 52 week low of Rs. 75.00 on 15-Apr-2021.

Last one week high and low of the scrip stood at Rs. 194.40 and Rs. 156.75 respectively. The current market cap of the company is Rs. 470.78 crore.

You Can Also Read This  Indiabulls Real Estate zooms on raising Rs 75 crore through NCDs

The promoters holding in the company stood at 70.34%, while Institutions and Non-Institutions held 0.12% and 29.54% respectively.

Jagsonpal Pharmaceuticals has entered into an agreement with Suvinys Developers for supply of product Dydrogesterone.

Suvinys Developers will supply Dydrogesterone to Jagsonpal Pharmaceuticals as per the terms and conditions as mentioned in the agreement.

You Can Also Read This  Zydus Cadila receives USFDA’s approval for Leflunomide Tablets

Jagsonpal Pharmaceutical is among India’s premiere pharmaceutical companies.

The company has substantial research and development, manufacturing, marketing and distribution facilities.